Clinical trials: Staphylococcal Infections
- Condition Staphylococcal Infections
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Staphylococcal Skin Infections, Streptococcal Infections
Pharmacokinetic Study,Ceftobiprole,Healthy Volunteers,Healthy Patients With End Stage Renal Disease
The purpose of this study is to characterize the pharmacokinetics (how drugs are absorbed in the body, how they are distributed within the body and how they are removed from the body over time) of ceftobiprole after a single…
- Trial name
- NCT01030731
- Testing
- Ceftobiprole
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Basilea Pharmaceutica
Staphylococcal Infections, Cardiovascular Diseases
StaphVAX in Cardiovascular Surgery Patients
S. aureus is the most common pathogen encountered in infection associated with cardiovascular surgery. StaphVAX® is a bivalent S.
- Conditions
- Staphylococcal Infections, Cardiovascular Diseases, Cardiovascular Surgical Procedures
- Trial name
- NCT00211913
- Testing
- S. aureus Type 5 & 8 Capsular Polysaccharide Conjugate
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Nabi Biopharmaceuticals
Staphylococcal Infections
V710 First-In-Man (FIM) Study (V710-001)
This is a randomized, Multicenter, double-blind (subject, investigator, and Merck Research Laboratories (MRL) clinical personnel directly involved in the study), placebo-controlled, dose-ranging study in healthy adults 18 to 55…
- Trial name
- NCT00303069
- Testing
- V710
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Staphylococcus Aureus
Evaluation of NDV-3A Vaccine in Preventing S. Aureus Colonization
The proposed study aims to further evaluate the safety and immunogenicity of a candidate S. aureus vaccine NDV-3A, as well as its efficacy against acquisition of S. aureus
- Trial name
- NCT03455309
- Testing
- NDV-3A
- Where
- United States
- Volunteers
- 382 people, healthy volunteers welcome
- Sponsor
- NovaDigm Therapeutics, Inc.
Staphylococcus Aureus Infection
A Clinical Study in Health Subjects to Evaluate 9MW1411 Injection
This is a Phase 1, first time in human study enrolling approximately 42 healthy adult subjects (18-45 yrs) from one study site. The purpose of this study is to evaluate the safety, tolerability and PK of MW14 in healthy adult…
- Trial name
- NCT04784312
- Testing
- 9MW1411 injection
- Where
- China
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
Staphylococcal Infections
Safety, Tolerability, and Immunogenicity of a Single Dose of Merck 0657nI Staphylococcus Aureus Vaccine With or Without Merck Aluminum Adjuvant (V710-002)
The purpose of this study was to evaluate the safety, tolerability, and immunogenicity of the Merck 0657nI S. aureus vaccine (V710) either with or without Merck Aluminum Adjuvant (MAA).
- Trial name
- NCT01324440
- Testing
- V710 (30 µg) with MAA, V710 (30 µg) without MAA
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Staphylococcal Sepsis
Safety and Pharmacokinetics Study in Adults for the Prevention of S. Epidermidis Infection in Low Birth Weight Infants
The purpose of this Phase 1 study is to evaluate the safety and pharmacokinetics of BSYX-A110 in a small number of healthy adult volunteers.
- Trial name
- NCT00636285
- Testing
- BSYX-A110
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Biosynexus Incorporated
Community Acquired Pneumonia, Staphylococcal Skin Infections
First Time in Man Trial for Friulimicin B
The purpose of this study is to study the safety of single doses and multiple doses of Friulimicin B in healthy volunteers. The level of Friulimicin B will be measured in the subjects blood and urine.
- Trial name
- NCT00492271
- Testing
- Friulimicin B
- Where
- Switzerland
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- MerLion Pharmaceuticals GmbH
Atopic Dermatitis
Observer-Blinded Dose Escalating, Single Dose to Study Safety and Antimicrobial Efficacy of Gel vs. Placebo
A Randomized, Observer-Blinded, Vehicle Controlled, Single Dose, Dose Escalating, Single Application Within-patient Bilateral Comparison. The goal is to determine the safety and tolerability of DBI-001 Gel vs.
- Trial name
- NCT04192513
- Testing
- J. lividum
- Where
- Dominican Republic
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- DermBiont, Inc.
Staphylococcal Infections, Joint Prosthesis
StaphVAX Immunogenicity in Orthopedic Implant Patients
S. aureus is the most common pathogen involved in prosthetic joint infection. StaphVAX® is a vaccine to prevent these infections, which conjugates the purified capsular polysaccharides of S. aureus to a carrier protein.
- Trial name
- NCT00211926
- Testing
- S. aureus Type 5 & 8 Capsular Polysaccharide Conjugate
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Nabi Biopharmaceuticals
Staphylococcus Aureus Infection
Study of the Nasal Decolonisation of Staphylococcus Aureus (SA) and the Safety and Tolerability of XF-73 Nasal Gel in Healthy Subjects
Study to determine the efficacy, safety and tolerability of two concentrations of XF-73 nasal gel in combination with body and face washing with chlorhexidine gluconate cloths in eradicating nasal carriage of Staphylococcus…
- Trial name
- NCT02282605
- Testing
- XF-73 nasal gel, Chlorhexidine gluconate 2% topical cloths
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Destiny Pharma Plc
Staphylococcal Infections, Candidiasis
Safety and Immunogenicity Study of a Recombinant Protein Vaccine (NDV-3) Against S.Aureus and Candida
This randomized, double-blind, placebo-controlled study is a first-in-human Phase 1 study using two dose levels of an investigational vaccine directed against S. aureus and Candida.
- Trial name
- NCT01273922
- Testing
- NDV-3 investigational vaccine
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- NovaDigm Therapeutics, Inc.
Staphylococcus Aureus
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4893 in Healthy Adult Subjects
This is a Phase 1, first time in human study enrolling approximately 33 healthy adult subjects (18-65 yrs) from one study site. The purpose of this study is to evaluate the safety, tolerability and PK of MEDI4893 in healthy adult…
- Trial name
- NCT01769417
- Testing
- MEDI4893
- Where
- United States
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Staphylococcal Infections
Evaluation of a Single Vaccination With One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to <65 Years
This is a first-in-human (Phase 1) and Phase 2 study of a single vaccination with one of three dose levels of an investigational vaccine against Staphylococcus aureus (SA4Ag).
- Trial name
- NCT01364571
- Testing
- SA4Ag vaccine low dose, Blood draw, Colonization swab sample
- Where
- 16 sites in United States
- Volunteers
- 456 people, healthy volunteers welcome
- Sponsor
- Pfizer
Obesity, Staphylococcal Skin Infections
A Study Evaluating the Pharmacokinetics of Ceftobiprole When Taken by Obese Patients
The primary objective of this study is to compare the pharmacokinetics (how drugs are absorbed in the body, how they are distributed within the body and how they are removed from the body over time) of ceftobiprole in morbidly…
- Conditions
- Obesity, Staphylococcal Skin Infections, Streptococcal Infections
- Trial name
- NCT01026558
- Testing
- Ceftobiprole
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Basilea Pharmaceutica
Infections, Staphylococcal
A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Staphylococcal Investigational Vaccine in Healthy Adults
The purpose of this study is to evaluate the safety, reactogenicity and immunogenicity of several formulations of an investigational Staphylococcal vaccine.
- Trial name
- NCT01160172
- Testing
- Staphylococcal investigational vaccine GSK2392103A, Staphylococcal investigational vaccine GSK2392105A, Staphylococcal investigational vaccine GSK2392106A
- Where
- Belgium
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Staphylococcal Infection
V710 Clinical Study in Healthy Male Japanese Subjects (V710-006) (COMPLETED)
This study is to evaluate the safety and immunogenicity of V710 in Japanese male subjects.
- Trial name
- NCT00735839
- Testing
- V710
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Bacterial Infections, Staphylococcal Vaccines
An Evaluation Of Three Dose Levels Of 3-Antigen Staphylococcus Aureus Vaccine (SA3Ag) In Healthy Adults
This study is a first-in-human (Phase 1) study using three dose levels of an investigational vaccine directed against Staphylococcus aureus (SA3Ag).
- Conditions
- Bacterial Infections, Staphylococcal Vaccines, Immunotherapy, Active, Staphylococcal Skin Infections
- Trial name
- NCT01018641
- Testing
- SA3Ag vaccine, Blood draw, Colonization swab samples
- Where
- 5 sites in Australia
- Volunteers
- 449 people, healthy volunteers welcome
- Sponsor
- Pfizer
Staphylococcal Infections
Evaluation of a Single Vaccination of One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) and a Single Dose Level of a 3-Antigen Staphylococcus Aureus Vaccine (SA3Ag) in Healthy Adults Aged 65 to <86 Years
This is a Phase 1 and Phase 2 study of a single vaccination with one of three dose levels of a 4-antigen investigational vaccine against Staphylococcus aureus (SA4Ag) and a single dose level of a 3-antigen Staphylococcus aureus…
- Trial name
- NCT01643941
- Testing
- SA4Ag vaccine low dose, Blood draw, Colonization swab sample
- Where
- 7 sites in United States
- Volunteers
- 284 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthcare Associated Infection, Nosocomial Infection
Red Light Photobiomodulation and Topical Disinfectants
The goal of this clinical trial is to evaluate the potential effects of photobiomodulation when used with topical disinfectants in the anterior nares of healthy adults.
- Conditions
- Healthcare Associated Infection, Nosocomial Infection, Surgical Site Infection
- Trial name
- NCT05797818
- Testing
- Methylene Blue Only, Chlorhexidine Gluconate Only, Methylene Blue + Chlorhexidine Gluconate
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Ondine Biomedical Inc.